Extended Data Fig. 3: Diagnostic performance of αPD1-GS in ICB nonresponsive models. | Nature Biomedical Engineering

Extended Data Fig. 3: Diagnostic performance of αPD1-GS in ICB nonresponsive models.

From: Urinary detection of early responses to checkpoint blockade and of resistance to it via protease-cleaved antibody-conjugated sensors

Extended Data Fig. 3

a, Average and b, individual tumour growth curves of CT26 tumour bearing mice treated with either αCTLA4-GS or matched IgG2 isotype control (Iso-GS) (two-way ANOVA with Sidak’s post-test and correction for multiple comparisons, ns = not significant, n = 10-11 biological replicates, error bars depict s.e.m.). Black arrows denote the treatment time points. c, Normalized urine fluorescence of mice with CT26 tumours after each administration of αCTLA4-GS or Iso-GS (two-way ANOVA with Sidak’s post-test and correction for multiple comparisons, ns = not significant, n = 10-11 biological replicates). d, Average and e, individual tumour growth curves of CT26 tumour bearing mice treated with αPD1-GS or matched IgG1 isotype control (Iso-GS) (two-way ANOVA with Sidak’s post-test and correction for multiple comparisons, ns = not significant, n = 6 biological replicates, error bars depict s.e.m.). Black arrows denote the treatment time points. f, Normalized urine fluorescence of mice with CT26 tumours after each administration of αPD1-GS or Iso-GS (two-way ANOVA with Sidak’s post-test and correction for multiple comparisons, ns = not significant, n = 6 biological replicates).

Source data

Back to article page